Polymeric implants, preferably containing a mixture of PEG and PLG, for controlled release of active agents, preferably a GNRH

Details for Australian Patent Application No. 2004313245 (hide)

Owner Durect Corporation

Inventors Gibson, John W.; Tipton, Arthur J.

Agent FB Rice

Pub. Number AU-B-2004313245

PCT Pub. Number WO2005/067889

Priority 60/533,301 30.12.03 US; 60/575,199 28.05.04 US; 60/563,377 19.04.04 US

Filing date 23 December 2004

Wipo publication date 28 July 2005

Acceptance publication date 14 April 2011

International Classifications

A61K 9/00 (2006.01) Medicinal preparations characterised by special physical form

A61K 9/16 (2006.01) Medicinal preparations characterised by special physical form - Agglomerates

A61K 9/70 (2006.01) Medicinal preparations characterised by special physical form - Web, sheet or filament bases

A61K 38/09 (2006.01) Medicinal preparations containing peptides

Event Publications

13 July 2006 Change of Name(s) of Applicant(s), Section 104

  Durect Corporation; Gibson, John W.; Tipton, Arthur J. The name of the applicant has been changed to Durect Corporation

20 July 2006 PCT application entered the National Phase

  PCT publication WO2005/067889 Priority application(s): WO2005/067889

14 April 2011 Application Accepted

  Published as AU-B-2004313245

11 August 2011 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004313246-(3-oxo-3, 4-dihydro-quinoxalin-2-yl-amino) - benzamide derivatives and related compound as glycogen phosphorylase inhibitors for the treatment of diabetes and obesity

2004313242-HIV gp41 HR2-derived synthetic peptides, and their use in therapy to inhibit transmission of human immunodeficiency virus